Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Tumors on withdrawal: Amino acid deficiency shrinks childhood tumors

No. 27 | 28/04/2022 | by Moos

Certain childhood tumors have an extreme need for amino acids. Scientists at the Hopp Children's Cancer Center Heidelberg (KiTZ), the German Cancer Research Center (DKFZ), the University of Heidelberg, and HI-STEM* gGmbH have now discovered the molecular mechanisms underlying this and how the cancer cells could be turned off.

The Hopp Children's Cancer Center Heidelberg (KiTZ) is a joint institution of the German Cancer Research Center (DKFZ), Heidelberg University Hospital (UKHD) and the University of Heidelberg (Uni HD).

The histologic section shows an accumulation of aggressive neuroblastoma cells in the center of the image.
© Westermann/DKFZ

Every year, approximately one in 100,000 children develops a new neuroblastoma, often in the first year of life. This makes neuroblastomas a relatively common group of tumors in children. They form in immature nerve tissue during embryonic development and occur mainly in the adrenal gland, spine, neck, chest, abdomen, and pelvis. Neuroblastomas are difficult to treat and often resistant to therapy. Infants and young children are particularly affected. In some cases, the tumor regresses completely without any therapy. In about half of the patients, however, it progresses inexorably despite highly intensive therapy.

An important regulator that determines the direction in which the disease develops is the cancer gene MYCN. Only recently it became known that this cancer gene sets the course for whether precursor cells develop into mature nerve cells or become malignant neuroblastoma cells. Neuroblastomas with unfavorable progression also carry hundreds of active copies of the MYCN gene in their genome. The high MYCN activity leads to profound changes in the metabolism of the cancer cells, because MYCN in turn switches on and off a large number of other genes. But what advantage does this give the cancer cell, and can this highly specialized network be specifically disrupted to actively fight the cancer cells?

These were the questions asked by the team of scientists led by Frank Westermann of the Hopp Children's Cancer Center Heidelberg (KiTZ) and the German Cancer Research Center (DKFZ), Andreas Trumpp, DKFZ and HI-STEM* gGmbH, and Thomas Höfer of DKFZ. In the present study, first authors Hamed Alborzinia and Andres Florez discovered that neuroblastoma cells with high MYCN activity need one thing in particular: the amino acid cysteine. Cysteine is an important building block for most cellular proteins and lipids. The fast-growing cancer cells need large amounts of these building blocks to produce new cells.

At the same time, cancer cells need cysteine to protect themselves from naturally occurring toxic peroxides that are produced conditionally by their highly active metabolism. "The cysteine hunger of neuroblastoma cells is so great that they use two pathways to obtain cysteine," says Sina Kreth, another first author of the study. "They use the import of the amino acid and additionally crank up an alternative synthetic pathway to obtain cysteine from the amino acid methionine," first author Lena Brückner adds.

However, it is precisely these adaptation processes that make the neuroblastoma cells sensitive. If the scientists deprived them of cysteine, the MYCN-driven tumor cells could no longer inactivate the toxic peroxides produced and died by ferroptosis, a special form of cell death. The research team then tested whether this process could be a potential Achilles heel for a therapy against malignant neuroblastoma in mice.

The scientists deliberately turned off the tap to the tumors: They blocked cysteine uptake, cysteine synthesis, and also switched off a key enzyme that normally prevents cancer cells from poisoning themselves with peroxides. The cancer cells then initiated their own self-destruction through ferroptosis, and the tumors shrank.

"Ferroptosis cell death was discovered only a few years ago, and the results now show for the first time not only in cell cultures but also in cancer-bearing mice how this process can be manipulated to kill highly aggressive human neuroblastoma cells by inducing ferroptosis," Hamed Alborzinia emphasizes.

The findings also provide a possible explanation for why some neuroblastomas with moderate MYCN activity in infants and young children simply disappear in some cases: "Cells basically take up less cysteine in the first years of life. Therefore, when they start to divide uncontrollably, they soon run out of cysteine reserves and ferroptotic cell death is initiated," Andres Florez explains. Some neuroblastomas without MYCN activity cannot escape this self-destruction and then simply die after a certain time when cysteine becomes scarce.

For high-risk patients with high MYCN activity, the study provides the first insights into how the balance between cysteine uptake, production, and consumption could possibly be disturbed in such a way that these cells also initiate their self-destruction. Whether the newly discovered principle will also prove effective in the therapy of neuroblastoma patients must now be tested in clinical trials.

* The Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM) gGmbH was founded in 2008 as a public-private partnership by the DKFZ and the Dietmar Hopp Foundation.

Alborzinia H, Flórez A.F., Kreth S., Brückner L.M. et al. MYCN mediates cysteine addiction and sensitizes neuroblastoma to Ferroptosis In: Nature Cancer 2022, DOI: 10.1038/s43018-022-00355-4

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institution in Germany. More than 1,300 scientists at the DKFZ investigate how cancer develops, identify cancer risk factors and search for new strategies to prevent people from developing cancer. They are developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to all questions on cancer.

Jointly with partners from the university hospitals, the DKFZ operates the National Center for Tumor Diseases (NCT) in Heidelberg and Dresden, and the Hopp Children's Cancer Center KiTZ in Heidelberg. In the German Consortium for Translational Cancer Research (DKTK), one of the six German Centers for Health Research, the DKFZ maintains translational centers at seven university partner locations. NCT and DKTK sites combine excellent university medicine with the high-profile research of the DKFZ. They contribute to the endeavor of transferring promising approaches from cancer research to the clinic and thus improving the chances of cancer patients.

The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.

RSS-Feed

Subscribe to our RSS-Feed.

to top
powered by webEdition CMS